Loading...
Market
Story
AbbVie Secures FDA Approval for Injectable Parkinson's Drug After Rejections on October 17
Oct 17, 2024, 08:36 PM
AbbVie has received approval from the FDA for a new injectable drug aimed at alleviating symptoms of Parkinson's disease. This approval comes after previous rejections and represents a significant advancement in treatment options for patients suffering from Parkinson's and related disorders. The drug has shown efficacy in reducing symptoms and improving motor fluctuations in clinical study participants. The approval has been welcomed by advocates and lawmakers, who emphasize the importance of accessible and effective medications for millions of families affected by these conditions.
View original story
Similar markets
Biogen • 25%
Roche • 25%
Pfizer • 25%
Other • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Leader • 25%
Top 3 • 25%
Top 5 • 25%
Not in Top 5 • 25%
Moderna • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Other • 25%
Acquisition of another company • 25%
Launch of a new drug • 25%
Restructuring or cost-cutting measures • 25%
Other strategic move • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Skyrizi • 25%
Rinvoq • 25%
Humira • 25%
Other • 25%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Johnson & Johnson • 25%
Merck • 25%
AstraZeneca • 25%
Other • 25%
Bristol-Myers Squibb • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
AbbVie • 25%
Bristol Myers Squibb • 25%
Another major pharmaceutical company • 25%
No new approvals • 25%
Takeda • 25%
Amgen • 25%
Novo Nordisk • 25%
Other • 25%